Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Clinical Diagnosis and Management of Acute Coronary Syndrome
share announcement

Clinical Diagnosis and Management of Acute Coronary Syndrome

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 20 June 2024 | Viewed by 2621

Special Issue Editors

Dr. Bimmer Claessen

E-Mail Website
Guest Editor
Heart Centre, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
Interests: complex PCI; vulnerable plaque imaging and treatment; antiplatelet strategies
Dr. Ronak Delewi

E-Mail Website
Guest Editor
Heart Centre, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
Interests: acute coronary syndromes; structural heart disease; clinical trials

Special Issue Information

Dear Colleagues,

Acute coronary syndrome (ACS) remains one of the most important causes of morbidity and mortality in modern clinical practice. The diagnosis and management of ACS continue to evolve significantly in contemporary clinical practice. The aim of this Special Issue is to provide original research and state-of-the-art review papers regarding important current trends in the diagnosis and management of ACS. While the editors welcome all submissions related to ACS, they will consider several subjects with particular interest including 1) research regarding rapid diagnosis algorithms using point-of-care biomarker tests, 2) treatment and identification of vulnerable plaques, and 3) antiplatelet strategies. We encourage researchers in the field of general and interventional cardiology to submit their manuscripts for this Special Issue.

Dr. Bimmer Claessen
Dr. Ronak Delewi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute coronary syndrome
  • diagnostic accuracy
  • Point-of-Care
  • vulnerable plaque
  • percutaneous coronary intervention
  • computed tomography coronary angiography
  • antiplatelet therapy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

0 pages, 1137 KiB  
Article
First-in-Human Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques: Rationale and Design of the DEBuT-LRP Study
by Anna van Veelen, I. Tarik Küçük, Federico H. Fuentes, Yirga Kahsay, Hector M. Garcia-Garcia, Ronak Delewi, Marcel A. M. Beijk, Alexander W. den Hartog, Maik J. Grundeken, M. Marije Vis, José P. S. Henriques and Bimmer E. P. M. Claessen
J. Clin. Med. 2023, 12(18), 5807; https://doi.org/10.3390/jcm12185807 - 06 Sep 2023
Cited by 1 | Viewed by 1099 | Correction
Abstract
Patients with non-obstructive lipid-rich plaques (LRPs) on combined intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) are at high risk for future events. Local pre-emptive percutaneous treatment of LRPs with a paclitaxel-eluting drug-coated balloon (PE-DCB) may be a novel therapeutic strategy to prevent future [...] Read more.
Patients with non-obstructive lipid-rich plaques (LRPs) on combined intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) are at high risk for future events. Local pre-emptive percutaneous treatment of LRPs with a paclitaxel-eluting drug-coated balloon (PE-DCB) may be a novel therapeutic strategy to prevent future adverse coronary events without leaving behind permanent coronary implants. In this pilot study, we aim to investigate the safety and feasibility of pre-emptive treatment with a PE-DCB of non-culprit non-obstructive LRPs by evaluating the change in maximum lipid core burden in a 4 mm segment (maxLCBImm4) after 9 months of follow up. Therefore, patients with non-ST-segment elevation acute coronary syndrome underwent 3-vessel IVUS-NIRS after treatment of the culprit lesion to identify additional non-obstructive non-culprit LRPs, which were subsequently treated with PE-DCB sized 1:1 to the lumen. We enrolled 45 patients of whom 20 patients (44%) with a non-culprit LRP were treated with PE-DCB. After 9 months, repeat coronary angiography with IVUS-NIRS will be performed. The primary endpoint at 9 months is the change in maxLCBImm4 in PE-DCB-treated LRPs. Secondary endpoints include clinical adverse events and IVUS-derived parameters such as plaque burden and luminal area. Clinical follow-up will continue until 1 year after enrollment. In conclusion, this first-in-human study will investigate the safety and feasibility of targeted pre-emptive PE-DCB treatment of LRPs to promote stabilization of vulnerable coronary plaque at risk for developing future adverse events. Full article
(This article belongs to the Special Issue Clinical Diagnosis and Management of Acute Coronary Syndrome)
►▼ Show Figures

Figure 1

14 pages, 2608 KiB  
Article
Conservative versus Invasive Strategy in Elderly Patients with Non-ST-Elevation Myocardial Infarction: Insights from the International POPular Age Registry
by Wout W. A. van den Broek, Marieke E. Gimbel, Dean R. P. P. Chan Pin Yin, Jaouad Azzahhafi, Renicus S. Hermanides, Craig Runnett, Robert F. Storey, David Austin, Rohit Oemrawsingh, Justin Cooke, Gavin Galasko, Ronald J. Walhout, Dirk A. A. M. Schellings, Stijn L. Brinckman, Hong Kie The, Martin G. Stoel, Antonius A. C. M. Heestermans, Debby Nicastia, Mireille E. Emans, Arnoud W. J. van ’t Hof, Hannes Alber, Robert Gerber, Paul F. M. M. van Bergen, Ismail Aksoy, Abdul Nasser, Paul Knaapen, Cees-Joost Botman, Anho Liem, Johannes C. Kelder and Jurriën M. ten Bergadd Show full author list remove Hide full author list
J. Clin. Med. 2023, 12(17), 5450; https://doi.org/10.3390/jcm12175450 - 22 Aug 2023
Cited by 2 | Viewed by 895
Abstract
This registry assessed the impact of conservative and invasive strategies on major adverse clinical events (MACE) in elderly patients with non-ST-elevation myocardial infarction (NSTEMI). Patients aged ≥75 years with NSTEMI were prospectively registered from European centers and followed up for one year. Outcomes [...] Read more.
This registry assessed the impact of conservative and invasive strategies on major adverse clinical events (MACE) in elderly patients with non-ST-elevation myocardial infarction (NSTEMI). Patients aged ≥75 years with NSTEMI were prospectively registered from European centers and followed up for one year. Outcomes were compared between conservative and invasive groups in the overall population and a propensity score-matched (PSM) cohort. MACE included cardiovascular death, acute coronary syndrome, and stroke. The study included 1190 patients (median age 80 years, 43% female). CAG was performed in 67% (N = 798), with two-thirds undergoing revascularization. Conservatively treated patients had higher baseline risk. After propensity score matching, 319 patient pairs were successfully matched. MACE occurred more frequently in the conservative group (total population 20% vs. 12%, adjHR 0.53, 95% CI 0.37–0.77, p = 0.001), remaining significant in the PSM cohort (18% vs. 12%, adjHR 0.50, 95% CI 0.31–0.81, p = 0.004). In conclusion, an early invasive strategy was associated with benefits over conservative management in elderly patients with NSTEMI. Risk factors associated with ischemia and bleeding should guide strategy selection rather than solely relying on age. Full article
(This article belongs to the Special Issue Clinical Diagnosis and Management of Acute Coronary Syndrome)
►▼ Show Figures

Figure 1

Other

Jump to: Research

2 pages, 183 KiB  
Correction
Correction: van Veelen et al. First-in-Human Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques: Rationale and Design of the DEBuT-LRP Study. J. Clin. Med. 2023, 12, 5807
by Anna van Veelen, I. Tarik Küçük, Federico H. Fuentes, Yirga Kahsay, Hector M. Garcia-Garcia, Ronak Delewi, Marcel A. M. Beijk, Alexander W. den Hartog, Maik J. Grundeken, M. Marije Vis, José P. S. Henriques and Bimmer E. P. M. Claessen
J. Clin. Med. 2024, 13(5), 1479; https://doi.org/10.3390/jcm13051479 - 04 Mar 2024
Viewed by 294
Abstract
In the original publication [...] Full article
(This article belongs to the Special Issue Clinical Diagnosis and Management of Acute Coronary Syndrome)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop